Low dose immunoglobulin g for treatment of severe sepsis and septic shock by unknown
POSTER PRESENTATION Open Access
Low dose immunoglobulin G for treatment of
severe sepsis and septic shock
Y Iizuka1*, M Sanui1, M Hayakawa2, S Uchino3, T Mayumi4, D Kudo5, S Saito3, K Takimoto6, K Yamakawa7,
Y Sasabuchi8
From ESICM LIVES 2015
Berlin, Germany. 3-7 October 2015
Introduction
As an adjunctive treatment in sepsis, patients administered
high-dose (0.9g/kg body weight) intravenous immunoglo-
bulin G (IvIgG) did not have a significant survival benefit
in a randomized control study (The SBITS study) (1).
However, low-dose ivIgG (5g/day 3days) might have some
utilities including earlier defervescence and improvements
of clinical signs and symptoms (2).
Objectives
In this retrospective cohort study of patients with severe
sepsis and septic shock, we investigated whether low-dose
IvIgG was associated with clinically important outcomes
including ICU mortality and in-hospital mortality.
Methods
This study is a preplanned retrospective analysis of a large
database created by Japan SEPTIC DIC study conducted
in 41 ICUs. This study investigated associations between
sepsis-related coagulopathy, anticoagulation therapies, and
clinical outcomes of 3195 adult patients with severe sepsis
and septic shock admitted to ICUs in Japan from January
2011 through December 2013. To estimate associ-
ations between IvIgG administration and mortalities,
multivariable logistic regression modeling and propensity
score-based matching were used for analysis with SPSS
version 22.
Results
IvIgG was administered in 976 patients (30.5%). Patients
administered ivIgG had significantly higher APACHEⅡ
scores (24.2 ± 8.8 vs. 22.7 ± 8.6, P < 0.001), and SOFA
scores at admission (10.4 ± 4.0 vs. 9.1 ± 4.0, P < 0.001).
ICU mortality was higher in patients with IvIgG (23.1%
vs. 18.4%, P = 0.003), but IvIgG was not associated with
ICU mortality after adjustment for cofactors (OR 1.121,
95%CI 0.879-1.430, P = 0.358). In-hospital mortality in
patients receiving IvIgG was similar to those not receiv-
ing IvIgG (34.7% vs 31.9% P = 0.118). In a propensity
score-matched analysis, both ICU mortality and in-hos-
pital mortality were not different between the groups
(22.4% vs. 19.1%, P = 0.088; and 33.7% vs. 31.8%, P =
0.388, respectively).
Conclusions
In our retrospective analysis of a large cohort of severe
sepsis and septic shock, administration of low-dose
IvIgG as adjunctive therapy for patients with severe sep-
sis and septic shock was not associated with a reduction
in ICU mortality and in-hospital mortality.
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